Cai Jing Wang·2025-09-08 05:05Core Insights - The company is actively expanding sales channels for its commercialized products beyond Toripalimab, focusing on enhancing revenue generation [1][2] - The management has outlined a clear strategy for business development, emphasizing collaboration and resource integration [2] Group 1: Product Commercialization - Mindewei® (Dexamethasone Hydrochloride Tablets) received conditional approval from the National Medical Products Administration in January 2023 and has achieved full-channel coverage by mid-2025, partnering with major e-commerce platforms and pharmacies [1] - Junmaikang® (Adalimumab) has eight approved indications and is included in the national medical insurance directory, with promotion managed by Maiwei Biotech [1] - Junshida® (Ongokrezi Monoclonal Antibody) was approved in October 2024 with three approved indications, and its commercialization is being advanced by partner Bochuang Pharmaceuticals [1] Group 2: Business Development Strategy - The company's business development team is actively pursuing connections between its pipeline and domestic and international resources, engaging in in-depth research and communication on multiple potential collaboration directions [2] - The company maintains an open and proactive attitude towards various types of business cooperation and aims to accelerate pipeline research and development [2] - Regular reviews of the pipeline will be conducted to identify candidates with business development potential and share innovative results promptly [2]